Home › SOLARINDS › Filing
🔔 Get instant alerts when SOLARINDS files quarterly results on BSE Start free trial →

Press Release

Filed: 03 Nov 2026, 14:29 IST Exchange: NSE Category: Financial Results — Press Release
Press Release - Q2FY27 - Consolidated revenue ₹3519 crore +69% y-y; H1 ₹7187 crore +70% y-y - EBITDA ₹1021 crore (29.02% margin) in Q2; H1 EBITDA ₹2045 crore (28.45% margin) - PAT ₹650 crore in Q2; ₹1316 crore in H1, up 80% and 84% y-y respectively - Order book ₹20178 crore provides strong future visibility - Domestic Explosives growth driven by mining, infrastructure demand - International Explosives expanding via acquisitions and greenfield projects - Defence business growing with new products and order pipeline - Confident of surpassing FY27 guidance based on strong H1 performance and order book
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 SOLARINDS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add SOLARINDS to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Solar Industries India Limited

Important. The summary above is generated automatically from Solar Industries India Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.